A systematic review and meta-analysis of vascularized lymph node transfer for breast cancer-related lymphedema

• Published in: Journal of vascular surgery. Venous and lymphatic disorders (New York, NY) Vol. 10; no. 3; pp. 786 - 795.e1
• Main Authors: Winters, Harm, Tielemans, Hanneke J.P., Paulus, Vera, Hummelink, Stefan, Slater, Nicholas J., Ulrich, Dietmar J.O.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2022
• Subjects: Breast cancer; Breast Cancer Lymphedema - diagnosis; Breast Cancer Lymphedema - etiology; Breast Cancer Lymphedema - therapy; Breast Neoplasms - complications; Female; Humans; Lymph node transfer; Lymph Nodes; Lymphedema; Lymphedema - surgery; Lymphedema - therapy; Quality of Life; Lymph node transfer; Breast cancer; Lymphedema; Lymphedema surgery
• ISSN: 2213-333X; 2213-3348
• DOI: 10.1016/j.jvsv.2021.08.023

Vascularized lymph node transfer (VLNT) has become an increasingly popular technique for treating lymphedema. However, although many studies have been performed, its efficacy in increasing patients’ quality of life (QoL) and reducing lymphedema in the affected body part has remained controversial. In the present systematic review, we summarized the evidence for VLNT for treating breast cancer-related lymphedema. The MEDLINE, Embase, and Cochrane Central databases were searched for studies of patients with breast cancer-related lymphedema who had received VLNT. The study methods were assessed using the MINORS (methodologic index for nonrandomized studies) tool. The primary outcomes were the change in volume difference between the arms and QoL. The secondary outcomes were skin infection, complications, and discontinuation of compression garment use. A total of 17 studies were included for qualitative synthesis and 8 for meta-analysis. The average reduction rate between the healthy and affected arms in the studies included in the meta-analysis was 40.31%. Five studies had evaluated QoL, and all five studies had reported that QoL was significantly increased. Eight studies had evaluated skin infections, of which three had reported the annual infection rates before and after surgery. In these studies, infection rate had decreased significantly. Three studies had described usage of compression garments. When the patients were pooled, 27 of 60 were able to discontinue use of the compression garment. The donor and recipient complication rates were 12.1% and 7.3%, respectively. The current evidence indicates that VLNT can improve the volume differences between the arms in patients with unilateral lymphedema by ∼40%. In addition, although determined from a few studies, it is likely that VLNT has a positive effect on patients’ QoL, the number of skin infections, and compression garment usage and coincided with a low complication rate.